Article

LASIK may be OK for some autoimmune patients

Although the FDA considers autoimmune diseases a contraindication for LASIK regardless of disease severity, a retrospective study suggests that the surgery may be appropriate in patients with well-controlled or inactive disease, said Ronald J. Smith, MD, MPH, of Beverly Hills.

Although the FDA considers autoimmune diseases a contraindication for LASIK regardless of disease severity, a retrospective study suggests that the surgery may be appropriate in patients with well-controlled or inactive disease, said Ronald J. Smith, MD, MPH, of Beverly Hills.

There have been no prospective clinical trials that have included patients with autoimmune diseases, although one case report cited a patient with lupus who developed corneal melt following PRK. Conflicting evidence has emerged from reports of cataract surgery on patients with autoimmune disease. However, this evidence should not necessarily be generalized to all patients with autoimmune diseases who are considering refractive surgery, Dr. Smith said.

He and colleague Robert Maloney, MD, of Los Angeles, conducted a retrospective analysis of patients undergoing LASIK at the Maloney Vision Institute, reviewing records for a history of any autoimmune disease. They identified 49 eyes of 26 patients with an autoimmune disease, most commonly lupus or rheumatoid arthritis. In all cases, the disease was inactive or the patients were stable on medication.

"None of our patients developed any of the corneal scleral complications," Dr. Smith said. "There were no corneal melts, no stage IV or central toxic keratopathy, no persistent epithelial defects, and no scleral melts."

These results were similar to the findings of several other recent studies.

"LASIK may be reasonable in patients with well-controlled or inactive autoimmune disease who are otherwise good candidates for LASIK," Dr. Smith said. He added that proper informed consent must be obtained.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.